Odanacatib

(2S )-N -(1- Cyanocyclopropyl )-4- fluoro-4- methyl-2- [[( 1S) -2,2,2 -trifluoro- 1-[ 4 - (4 - methylsulfonylphenyl ) phenyl] ethyl] amino] pentaneamide (IUPAC)

Enzyme inhibitor

Template: Infobox chemical / molecular formula search available

Odanacatib, development code MK- 0822, is an experimental drug for the treatment of osteoporosis and bone metastases.

Mechanism of Action

Odanacatib selectively blocks the enzyme cathepsin K. This enzyme plays in the degradation of bone matrix by osteoclasts play a key role.

The drug was developed by MSD Sharp & Dohme.

Clinical Trials

Odanacatib is still no authorized medicinal product. The substance is currently in phase III clinical development for the treatment of osteoporosis. When caused by breast cancer bone metastases odanacatib was in Phase II

Further Reading

• B. Hellwig: odanacatib for the treatment of osteoporosis. In: German Apotheker Zeitung of December 21, 2010
• Isabel E., C. Mellon, et al Difluoroethylamines as to amide isostere in inhibitors of cathepsin K. In: Bioorganic & medicinal chemistry letters Volume 21, Number 3, February 2011, pp. 920-923, ISSN 1464-3405. doi: 10.1016/j.bmcl.2010.12.070. PMID 21,232,956th
• JL Pérez- Castrillón, F. Pinacho, D. De Luis, M. Lopez- Menendez, A. Dueñas Laita: odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. In: Journal of osteoporosis band in 2010, 2010, pp., ISSN 2042-0064. doi: 10.4061/2010/401581. PMID 20,948,576th PMC 2951121 (Free full text ).
• WC Black: peptidomimetic inhibitors of cathepsin K. In: Current topics in medicinal chemistry Volume 10, Number 7, 2010, pp. 745-751, ISSN 1873-4294. PMID 20,337,585th (Review).
• C. Le Gall, E. Bonnelye, P. Clézardin: Cathepsin K inhibitors as treatment of bone metastasis. In: Current opinion in supportive and palliative care Volume 2, Number 3, September 2008, pp. 218-222, ISSN 1751-4266. doi: 10.1097/SPC.0b013e32830baea9, PMID 18,685,424th